Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan for severe COVID-19 respiratory complications
2020-005104-20Phase 2Terminated
- Sponsor
- Noorik Biopharmaceuticals AG
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) comparing Ambrisentan with Placebo (2 arms). Primary endpoint: Progression to respiratory failure or death. Started May 2022; status: terminated.
02
Drugs
ambrisentan
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2020-005104-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005104-20.